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Abstract
Background: Schizophrenia is a severe, disabling and prevalent mental disorder without cure and with a variable,
incomplete pharmacotherapeutic response. Prior to onset in adolescence or young adulthood a prodromal period
of abnormal symptoms lasting weeks to years has been identified and operationalized as clinically high risk (CHR)
for schizophrenia. However, only a minority of subjects prospectively identified with CHR convert to schizophrenia,
thereby limiting enthusiasm for early intervention(s). This study utilized objective resting electroencephalogram
(EEG) quantification to determine whether CHR constitutes a cohesive entity and an evoked potential to assess
CHR cortical auditory processing.
Methods: This study constitutes an EEG-based quantitative neurophysiological comparison between two unmedicated
subject groups: 35 neurotypical controls (CON) and 22 CHR patients. After artifact management, principal component
analysis (PCA) identified EEG spectral and spectral coherence factors described by associated loading patterns.
Discriminant function analysis (DFA) determined factors’ discrimination success between subjects in the CON and
CHR groups. Loading patterns on DFA-selected factors described CHR-specific spectral and coherence differences
when compared to controls. The frequency modulated auditory evoked response (FMAER) explored functional
CON–CHR differences within the superior temporal gyri.
Results: Variable reduction by PCA identified 40 coherence-based factors explaining 77.8 % of the total variance
and 40 spectral factors explaining 95.9 % of the variance. DFA demonstrated significant CON–CHR group difference
(P <0.00001) and successful jackknifed subject classification (CON, 85.7 %; CHR, 86.4 % correct). The population
distribution plotted along the canonical discriminant variable was clearly bimodal. Coherence factors delineated
loading patterns of altered connectivity primarily involving the bilateral posterior temporal electrodes. However,
FMAER analysis showed no CON–CHR group differences.
Conclusions: CHR subjects form a cohesive group, significantly separable from CON subjects by EEG-derived
indices. Symptoms of CHR may relate to altered connectivity with the posterior temporal regions but not to
primary auditory processing abnormalities within these regions.
Keywords: Biomarker, Clinical high risk, Discriminant function analysis, Electroencephalogram spectral coherence,
Frequency modulated auditory evoked response, Principal component analysis, Prodrome, Schizophrenia
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Background
Schizophrenia is a chronic, severe, and disabling mental
disorder characterized by deficits in thought processes,
perceptions, and emotional responsiveness. Further-
more, it is associated with symptoms including cogni-
tive disorganization, hallucinations, and paranoia. The
prevalence per year in the USA is 1.1 % of the adult popu-
lation (www.nimh.nih.gov/health/topics/schizophrenia).
The yearly incidence for psychotic disorders has been
reported recently in Australia as 28 per 100,000 population,
with rates peaking in adolescence and young adulthood
[1]. However, a longitudinal register-based case finding
approach, as opposed to a first-contact sampling approach,
clarified that the incidence of schizophrenia is likely many
times higher than commonly reported, reaching as high as
69 per 100,000 patients per year in the USA [2].
Medications have failed to ‘cure’ schizophrenia and
response to pharmacologic intervention is reported to
be quite variable [3], which may relate in part to poor
medication compliance [4] and may also have biological
underpinnings. For example, 30 % of patients with inad-
equate medication response had a group-specific magnetic
resonance imaging (MRI) pattern of marked frontal atrophy
[5]. Many publications suggest that, although schizophrenia
cannot be medically ‘cured’, various support strategies
including social, psychological, and environmental – as
well as pharmacologic – may prove substantially ameli-
orative and suggest that the course of schizophrenia be
considered ‘uneven’ rather than ‘chronic’ [6–8].
Schizophrenia has been increasingly viewed from a
developmental perspective. Full psychosis appears to
represent a later aspect of the disorder. This raises the
possibility that medical and/or pharmacologic interven-
tions provided early might be of greater help to patients in
the long term. As reviewed by Larson et al. [3], prior to
onset of diagnosed schizophrenia in adolescence or young
adulthood, and prior to persistent psychosis, there may be
a ‘prodromal’ or clinical high risk (CHR) period, lasting
from several weeks to several years, during which aberrant
behaviors are evident.
Although the notion of neurodevelopmental influences
upon schizophrenia originally arose from postulated
changes in fetal brain development [9], more recent think-
ing also suggests a contribution from abnormalities during
adolescent brain development. Larson et al. [3] summarized
that “…persons later diagnosed with schizophrenia …[may
show]… early intellectual and neuromotor disabilities”
[10–14]. By the first episode of psychosis, those affected
on average exhibit slightly larger cerebral ventricles and
slightly less central gray matter than healthy controls [15].
These findings support the notion that at least part of the
disease process appears to be developmental.
CHR for schizophrenia is typically observed in adoles-
cents and young adults who manifest disturbances in stress
tolerance, perception, cognitive function, language, motor
function, energy, and initiative [16]. Although paranoia
and hallucinations may be intermittently reported dur-
ing the CHR phase, they are recognized by the patient
as ‘not real’. The CHR phase ‘ends’ and the diagnosis of
psychosis reached when the episodes of paranoia and
hallucinations become much more frequent and reality
testing wanes. Approximately 20–40 % of subjects with
CHR go on to develop psychosis and full-onset schizo-
phrenia [17–22]. Approximately 60–80 % of the subjects
with CHR who proceed from prodrome to psychosis can
be variably predicted based upon severity of pre-psychotic
symptomatology [3].
The ultimate outcome of those patients with CHR symp-
toms who do not ‘convert’ is poorly established; most con-
tinue to exhibit an array of cognitive and behavioral issues.
Some are later diagnosed with schizotypal disorder, in the
absence of psychosis. Some investigators have questioned
whether subjects with CHR symptoms, who do not convert
to schizophrenia, should constitute a separate syndrome
[23]. Treatment of CHR with atypical antipsychotics, anti-
depressants, cognitive therapy, or fish oils may result in be-
havioral improvement; however, initial favorable response
to these treatments may not result in long term benefits fol-
lowing treatment cessation [3, 24–29]. A more recent study
suggests that fish oils may be of preventative value [30].
The rate of non-conversion, the difficulties prospectively
identifying the converters, and the risks of available treat-
ments and stigmatization has made preventive treatment
complex.
MRI studies of CHR have variably documented findings
of reduction in frontal and temporal grey matter volumes
with suggestion that such imaging data could help deter-
mine the risk of psychotic manifestations [15, 31–33].
However, an important study by Owens et al. [34] served
to diminish these expectations. These authors contrasted
MRI-acquired measures of prefrontal cortex grey matter
volume reductions and of neuropsychological measures of
mental executive function in close relatives of patients
with schizophrenia. MRI prefrontal abnormalities were
not shown to be familial whereas the neuropsychological
findings were familial. The authors concluded “…that
the well-recognized prefrontal volume reductions …[in
schizophrenia]… are not related to the same familial in-
fluences that increase schizophrenia liability and, instead,
may be attributable to illness related biological changes
or indeed confounded by illness trajectory, chronicity,
medication or substance abuse, or in fact a combination
of some or all…” [34].
As has been summarized [35], it remains generally agreed
that electroencephalogram (EEG) evaluation by traditional,
unaided visual inspection bears scant clinical or scientific
fruit for the study of psychiatric patients – aside from
its value in excluding epilepsy. This contrasts with an
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abundance of published evidence that numerical quantifica-
tion of EEG by spectral and related spectral coherence ana-
lyses have demonstrated “…high proportions of abnormal
findings… with good concordance and high specificity…
across numerous studies… [in psychiatric disorders]” [36].
Spectral analysis refers to the quantitative analysis of EEG
frequency across spectral bands (e.g. delta, theta, alpha,
beta, and gamma) typically by Fast Fourier Transform
(FFT) [37, 38]. Spectral coherence refers to the assessment,
on a frequency by frequency basis, of the phase difference
between the signals from two EEG channels as compared
over time. As Duffy and Als stated [35], “Spectral coherence
is a measure of synchronization between two… [EEG]… sig-
nals based mainly on phase consistency; that is, two signals
may have different phases… [differing relative temporal
shifts]… but high coherence occurs when this phase differ-
ence tends to remain constant over time” [39]. High coher-
ence values are taken as a measure of strong connectivity
or coupling between the brain regions that produce the
compared EEG signals [37].
Early studies of EEG spectral background in schizophre-
nia demonstrated excessive frontal delta slowing [40, 41];
however, a later study demonstrated that a major compo-
nent of the frontal slowing could be attributed to residual
frontal eye blink delta band artifact that may survive
visually-based attempts at blink removal. Eye blinking has
been documented to be more prominent in subjects with
schizophrenia [42]. Furthermore, increased spontaneous
eye blink frequency has also been well-documented in
schizophrenia [43].
Many studies have subsequently evaluated EEG spectral
coherence in schizophrenia [44–50]; overall results sug-
gested an increase of both inter- and intra-hemispheric
coherence. Indeed, Mann et al. [46] concluded, on the
basis of their group data analyses, that “Increased coher-
ence might be assumed to be a vulnerability marker for
schizophrenia reflecting maldevelopment of the brain be-
fore onset of the disorder.” However, during hallucinations,
working memory tests and photic stimulation, others
have found that coherence may be relatively reduced in
schizophrenia [44, 48, 50].
Recently, there has been a focus on the gamma EEG
spectral band in schizophrenia [51–60]. This interest
arises as cortical gamma oscillation appears to be involved
in both local and large-scale neuronal synchronization
underlying a number of perceptual and higher order cog-
nitive functions of the sort often found to be abnormal in
schizophrenia [51]. Unfortunately, the background EEG
gamma spectral band and the spectral band of ambient
waking scalp muscle activity, as evidenced in scalp EEG
recordings, almost exactly overlap [61]. It has further been
observed that ‘thinking’ activates scalp muscle artifact
[62]. In addition, the induced gamma-band EEG response
(iGBR) recorded on the scalp in response to external
stimuli, such as in evoked potential studies, is widely as-
sumed to reflect synchronous neural oscillation associated
with object representation, attention, memory, and con-
sciousness. However, it has been suggested that the visual
iGBR recorded within scalp EEG may actually reflect
properties of visually induced miniature saccade dynamics
rather than neuronal oscillations [63, 64], although this
has been contested [65]. More recently, it has been re-
ported that auditory iGBR recorded on the scalp may also
be affected by saccadic muscle activity [66]. Hence, until
signal processing reaches the point where scalp muscle-
generated gamma artifact and true scalp recorded cortical
gamma activity contributions can be differentiated cleanly
and reliably within traditional EEG recordings, scalp fre-
quencies above 30 Hz (gamma) must be considered to be
unreliable for the purposes of spectral and coherence ana-
lyses, since gamma spectral data appear to be seriously
contaminated by background and/or induced muscle ac-
tivity. Clinical differences of scalp EEG activity between
groups in a comparison study of schizophrenic patients
and neurotypical control (CON) subjects could result in
spurious, albeit statistically significant, high frequency
gamma band spectral and/or coherence between groups.
To quote Whitham et al. [62] “…severe restrictions exist on
utilizing scalp recordings for high frequency EEG”.
The intent of the current study was to search for con-
sistent scalp EEG differences (by quantitative spectral
and spectral coherence analyses) between patients with
CHR for schizophrenia and CON subjects. The goal was
to determine (1) whether ambient, waking state EEG re-
cordings provide data which allow reliable group separ-
ation; (2) whether the variables best separating the groups
contain important information regarding the physiological
nature of group difference; and (3) whether a composite,
multivariate ‘discriminant function’ might be developed to
serve as a potential biomarker [67] for CHR schizophrenia.
In addition to gathering and analyzing resting EEG, a
steady-state evoked potential, the frequency modulated
evoked response (FMAER), was explored. The FMAER
arises from the superior temporal (STG), bilaterally,
and its use may facilitate physiological investigation of
receptive language processing. The FMAER has shown
abnormalities in children with a history of sudden-onset
regressive autism [68, 69]. The STG is a site of interest
having recently been suggested, by Fulham et al. [70], as a
marker of abnormal functioning by ‘mismatch negativity’ in
schizophrenia and prodrome, and by Oertel et al. [71, 72]
as sources of auditory dysfunction in schizophrenia.
To obviate contamination by eye and or muscle artifact
in the current study, a multi-step methodological ap-
proach was employed that was successfully used by the
first author in the evaluation of group differences between
children within the autism spectrum and CON subjects
[35]. Furthermore, the full EEG analytic approach also
Duffy et al. BMC Medicine  (2015) 13:276 Page 3 of 17
relies upon the computational reduction into a manage-
able number of factors of the large number of coher-
ence and spectral variables produced by single subjects.
This computational process facilitates an objective ap-
proach to data management for subsequent group analyses
[73, 74]. It obviates the need for a priori preselection of a
subset of coherence variables in order to avoid Type 1 and
2 statistical errors [74, 75].
Methods
Venue
All neurophysiological data collection and analysis was
performed under the direction and supervision of the
first author at the Developmental Neurophysiology La-
boratory, Department of Neurology, Boston Children’s
Hospital (BCH), a university-affiliated (Harvard Medical
School) academic medical center.
Subjects
Patients with Schizophrenia Prodrome Syndrome (CHR)
The CHR screening assessment included administration
of the Schedule for Affective Disorders and Schizophrenia
for School-Age Children-Present and Lifetime Version
[76]; the K-SADS, as it is known, constitutes a validated
semi-structured interview used to diagnose mood, anxiety,
substance abuse, and psychotic disorders in youth under
the age of 18. Both participant and parent/guardian report
of the participant’s symptom history were solicited for the
current study.
A number of tests/indices have been devised in order to
quantify identification and study of the CHR state [3, 77].
The current study employed the Scale of Prodromal
Symptoms (SOPS) [78, 79]. The SOPS is embedded within
an interview form, the Structured Interview for Prodromal
Syndromes (SIPS), designed to diagnose prodromal (CHR)
syndromes according to published criteria and to rate se-
verity of CHR symptoms [19]. While the SIPS serves to
define/identify the CHR state it does not in itself serve to
identify later development of psychosis. The SIPS and the
SOPS [80] were administered to all participants as part of
the screening.
SIPS/SOPS raters were certified through a standard
1½-day training program developed by the assessment’s
creators at Yale University’s PRIME Research Clinic. At
the start of the current study, raters also attended the
Boston site for the North American Prodromal Longitu-
dinal Study (NAPLS-2) to study SIPS interview collection
and scoring for 9 months to ensure consistent ratings
across sites. Among the current study sample, 66 (97 %) of
the SIPS/SOPS were performed by BCH staff; SIPS/SOPS
scores for the remaining two participants were provided by
their referral source, one from the NAPLS-2 and one from
the Social Neuroscience and Psychopathology Laboratory
of Harvard University, as they had been assessed at these
laboratories within 30 days of entering the current study.
In addition, information about past medical history,
medication usage, school functioning, and academic func-
tioning was obtained. The participant’s parent/guardian
and treating clinician were questioned to determine that
the participant was functioning at grade level in a regular
classroom without special education services and was
without any other evidence of intellectual and/or academic
disability. To further screen for academic and intellectual
function outside normal range, the Scales of Independent
Behavior-Revised was performed; this comprehensive scale
constitutes a norm-referenced assessment of adaptive and
maladaptive behaviors [81]. Only participants with positive
SIPS/SOS scores but without evidence of academic or in-
tellectual disability were included in the current study.
On the day of the laboratory visit, the participant’s
parent/guardian completed a demographic questionnaire
that asked for report of the participant’s demographic in-
formation and medication usage. Parents/guardians were
asked to provide consent for review of medical records to
further characterize participants’ mental health history. If
more than 1 month had elapsed since the screening
assessment, participants were re-administered the SIPS/
SOPS to confirm that the participant remained within
their previously determined clinical group. No participant
was reclassified based upon reassessment.
Study subjects were recruited, under the direction of
the senior author, from among three sources: clinical refer-
rals to the BCH outpatient psychiatric clinic, the NAPLS-2
program, and the Social Neuroscience and Psychopathology
Laboratory. Inclusion criteria were (1) a clinical diagnosis
of ‘schizophrenia prodromal (CHR) syndrome’, including
documentation by a senior staff psychiatrist of the patient’s
report of intermittent cognitive distortions (e.g. hallucina-
tions, paranoia, delusions); (2) positive SOPS scores from
the SIPS as administered by trained and certified technol-
ogists and confirmed by a staff psychiatrist; and (3) written
agreement as required by the BCH Institutional Review
Board (IRB) of the patient and/or parent/guardian to par-
ticipate in the study. Exclusion criteria were the presence
of any of the following: (1) co-existing primary neurologic
syndromes (e.g. Trisomy X or Klienfelter’s syndromes,
tuberous sclerosis, traumatic brain injury, global develop-
mental delay, developmental dysphasia, hydrocephalus,
hemiparesis, or any other known syndromes affecting
brain development); (2) coexisting primary psychiatric
syndromes (e.g. depression, bipolar disorder, attention
deficit hyperactivity disorder, obsessive-compulsive dis-
order); (3) clinical seizure disorders or results of prior
EEG readings suggestive of an active seizure disorder or
epileptic encephalopathy; (4) report of major medical
illnesses (e.g. diabetes, severe asthma, cardiovascular
abnormality, endocrine abnormality, etc.); (5) taking
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prescription medication(s) at the time of study; or (6)
significant primary sensory disorders (e.g. blindness
and/or deafness).
Healthy, CON subjects
Healthy CON subjects were recruited by poster and col-
league/acquaintance referral. None were recruited from
within families of the subjects with schizophrenia pro-
drome syndrome. Controls were screened by the same
procedure as described above for the CHR subjects. Inclu-
sion criteria required (1) the absence of any symptoms of
schizophrenia and (2) signed IRB consent as indicated
above. Exclusion criteria were the presence of any of the
following: (1) any neurological, psychiatric, and/or medical
illnesses and/or primary sensory disorders, as for the CHR
(prodrome) group spelled out above; (2) family history of
schizophrenia or other major mental illness; (3) history of
drug abuse; (4) non-specific ‘suspicious’ affect, appearance,
or behavior as observed by the study personnel; or (5) tak-
ing prescription medication(s) at the time of study.
IRB approval
All subjects and/or their families, as age appropriate,
gave written informed consent in accordance with proto-
cols approved by the IRB of the BCH Office of Clinical
Investigation. The approved protocol is in full compli-
ance with the Helsinki declaration.
Data acquisition
Neurophysiology recording: EEG data collection and initial
processing
All subjects’ electrophysiological data obtained for this
study were gathered by technologists trained and su-
pervised by the first author, an experienced academic
clinical electroencephalographer. Data were collected with
an EGI™ 128 channel geodesic net system (Electrical
Geodesics Inc., Eugene, OR, USA) along with a single
information channel dedicated to a stimulus trial marker
utilized for evoked potential collections (see FMAER
below). A conductive gel rather than a salt solution was
employed with the electrodes. Disadvantages of salt-
soaked sponge electrode use include inter-electrode
conductive ‘salt bridges’ and high electrode-scalp im-
pedance due to more rapid drying out, both of which
may lead to a difficult-to-detect increase in artifact. All
subjects were studied in a sound and electronically
(Faraday) shielded chamber and were visible and easily
accessible to the technologist via one-way mirror win-
dow and door. The recording equipment stood outside
of and immediately adjacent to the recording chamber.
Data were sampled at 500 Hz with 0.1–100 Hz EEG
band pass. Several separate epochs of eyes closed, waking
state data were obtained over the course of the study
with frequent breaks and verbal interchange to facilitate
alertness. Approximately a total of 20 minutes of appar-
ently artifact-free waking EEG was recorded per subject.
Eyes closed, waking state ambient EEG recordings were
temporally interdigitated with sessions of evoked potential
recordings (see below, FMAER). Frequent rest breaks were
built in as indicated. After conclusion of data collection,
all research subjects with electrode nets in place under-
went photogrammetry with an 11 camera-based EGI
system, so as to establish the precise position of the
128 net electrodes and thus to facilitate off-line mapping
to standard EEG electrode positions for comparative
purposes. Data were then de-artifacted (see below, Artifact
management – part 1 and part 2), re-montaged by 3D
spline interpolation, and signal averaged as indicated
(FMAER) by BESA™ software (BESA GmbH, Gräfelfing,
Germany). Original unprocessed data were permanently
archived within a Developmental Neurophysiology
Laboratory database.
For subsequent analysis, EEG, spectral, coherence, and
FMAER data were additionally reduced in number by
BESA using 3D spline interpolation to 24 standard EEG
locations (FP1, FP2, F7, F3, FZ, F4, F8, T7, C3, CZ, C4,
T8, P7, P3, PZ, P4, P8, O1, OZ, O2, FT9, FT10, TP9,
TP10 – see Fig. 1 for standard EEG electrode place-
ment), bandpass filtered from 0.5–50 Hz, mains filtered
at 60 Hz, and down-sampled to 256 Hz so as to reduce data
Fig. 1 Standard EEG electrode names and positions. Head in vertex
view, nose above, left ear to left. EEG electrodes: Z, Midline; FZ,
Midline frontal; CZ, Midline central; PZ, Midline parietal; OZ, Midline
occipital. Even numbers, right hemisphere locations; odd numbers,
left hemisphere locations: Fp, Frontopolar; F, Frontal; C, Central; T,
Temporal; P, Parietal; O, Occipital. The standard 19, 10–20 electrodes
are shown as black circles. An additional subset of five, 10–10
electrodes are shown as open circles. This figure is reproduced from
a prior publication [35] with permission
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dimensionality and facilitate comparison to data gathered
with more common lower temporal and spatial resolution
recording systems.
Neurophysiology recording: the Frequency Modulated
Auditory Evoked Response (FMAER)
The FMAER stimulus was initially derived by Green and
Stefanatos [82–86] as a means to assess the temporal
lobes’ ability to decode rapidly changing speech patterns,
essential to the accurate detection of phonemes and, in
turn, essential for language decoding and ultimately lan-
guage comprehension. By means of source analysis the
FMAER has been shown in neurotypical subjects to arise
from both STG [68]. The FMAER is formed by starting
with a 1000 Hz sine wave and frequency, modulating it
with another 10 Hz sine wave, which results in ‘warb-
ling’, and then further modulating it by slowly turning
the warbling on and off with another 4 Hz sine wave
[68]. A trial marker locked to the onset of one second of
the 4 Hz sine wave and saved with concurrently re-
corded EEG produces, after signal averaging, a scalp re-
corded 4 Hz sine wave in normal subjects. The FMAER
stimulus and trial marker are created by a stand-alone
Spark2 generator (Mind Spark Inc., Newton, MA, USA).
The auditory signal is bi-aurally presented by speakers at
78 db sound pressure level.
The FMAER response may be absent in the Landau-
Kleffner syndrome when language deteriorates [64] and
in autistic children with histories of rapid language and/
or behavioral regression [65]. Successful pharmacologic
treatment may improve receptive and expressive language
function and restore a previously absent FMAER [64, 65].
FMAER spectral analysis has also shown that the FMAER
scalp response may be as much ‘distorted’ as ‘absent’ in re-
gressive autism associated with language loss [65].
Measurement issues and solutions: artifact management –
part 1
After each subject’s participation in the EEG study, EEG
epochs were inspected by the EEG technologist to visually
identify which epochs were recorded during breaks for re-
laxation, or showed movement artifact, electrode artifact,
eye blink storms, drowsiness, epileptiform discharges, and/
or bursts of muscle activity. When so identified, they were
marked for exclusion from all subsequent analyses. The
EEG technologist’s results were reviewed for accuracy by
the first author, who then removed remaining eye blink and
eye movement artifacts, which may be surprisingly promin-
ent even during the eyes closed state, by utilization of the
source component technique [87–89] as implemented in
BESA software. These combined techniques resulted in
EEG data that appeared largely artifact free, with rare
exceptions of low level temporal muscle artifact and per-
sisting low voltage frontal and anterior temporal slow eye
movement, which however may contaminate subsequent
analyses. The final reduction of any persisting contamin-
ation of processed variables (coherence) is discussed below
under Artifact management – part 2.
Data processing
Calculation of spectral coherence and spectral variables
As previously described [35], 8–20 minutes of eyes closed,
awake state EEG cycles per subject were transformed
within BESA to the Laplacian or current source density
reference. This approach provided reference-independent
data that are primarily sensitive to underlying cortex and
relatively insensitive to deep/remote EEG sources. Use of
current source density reduces spurious effects of volume
conduction upon coherence by emphasizing sources at
small spatial scales [90].
Spectral coherence was calculated using a Nicolet™
(Nicolet Biomedical Inc., Madison, WI, USA) software
package, according to the conventions recommended by
van Drongelen [37, p. 143–4, equations 8.40, 8.44]. In
practice, coherence is typically estimated by averaging
over several epochs or frequency bands [37]. In the current
project, a series of 2 second epochs was utilized to process
available EEG segments. Spectral coherence measures were
derived from the 1–32 Hz range, in 16 2-Hz-wide spectral
bands resulting in 4,416 unique coherence variables. The
24 × 24 electrode coherence matrix yields coherence values
where the matrix diagonal has a value of 1 – each electrode
to itself – and half of the 552 remaining values duplicate
the other half. This results in 276 unique coherences per
spectral band. Multiplication by the 16 spectral bands in
turn results in 4,416 unique spectral coherence values per
subject [35].
Standard spectral data were calculated using the com-
mon average reference by FFT over the same frequency
range noted above and based upon the FFT algorithm
described in Press et al. [38, p. 411–2]. Resulting spectral
data were utilized in order to approximate residual
artifact contamination (see Artifact management – part 2)
and as potential predictor variables. Per subject, the 24
EEG channels and 64 spectral bands per channel result in
1,536 spectral data values.
Measurement issues and solutions: artifact management –
part 2
As previously detailed [35], visual inspection or direct
elimination of electrodes and/or frequencies where a
particular artifact is most easily apparent do not remove
all artifact from an EEG data set on their own. An estab-
lished approach to further reduce any persisting artifact
contamination of processed coherence data involves
multivariate regression. Semlitsch et al. [91] demonstrated
that, after identifying a signal that is proportional to a
known source of artifact, this signal’s contribution to
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scalp recorded data may be diminished by statistical regres-
sion procedures. As also previously detailed [35], persisting
vertical eye movements and blinks produce slow EEG delta
spectral signals in the frontopolar channels FP1 and FP2.
Such artifact contribution may be estimated by the average
of the 0.5 and 1.0 Hz spectral components from these
channels after EEG spectral analysis by FFT of common
average referenced data. Similarly, horizontal eye move-
ments may be estimated by the average of the 0.5–1.0 Hz
spectral components from anterior temporal electrodes F7
and F8. Little meaningful EEG information of brain origin
is typically found at this slow frequency in these channels
in the absence of extreme pathology. Muscle activity tends
to peak at frequencies above those of current interest. Ac-
cordingly, 30–32 Hz spectral components were considered
to be largely representative of muscle contamination, espe-
cially as recorded from the separate averages of prefrontal
(FP1, FP2), anterior temporal (F7, F8), mid-temporal (T7,
T8), and posterior temporal (P7, P8) electrodes. These
electrodes are most often contaminated by muscle artifact
as they are physically closest to the source of the artifact,
namely the frontal and temporal muscles. The steps
employed in the current study involved, first, the fitting of
a linear regression model where the dependent variables
were those targeted for artifact reduction and the inde-
pendent variables were those chosen as representative of
remaining artifacts; second, the extraction of the residuals,
which now represented the targeted data after artifact re-
moval; and, third, the use of the residuals in subsequent
analyses. The six artifact measures, two very slow delta
and four high frequency beta measures, were submitted as
independent variables to a multiple regression analysis
(BMDP2007™-6R) [92] in order to individually predict
each of the coherence variables (see below), which were
treated as the dependent variables. The residuals of the
dependent variables, now uncorrelated with the chosen in-
dependent artifact variables, were used in the subsequent
analyses. The above regressions were performed separately
on both spectral and coherence data sets prior to principal
components analysis (PCA; see below).
Prevention of capitalization upon chance: variable number
reduction by creation of spectral and spectral coherence
factors
Spectral and spectral coherence analyses produce many
variables per subject. Steps must be taken to avoid
capitalization on chance, which may result from the use of
too many variables. Typically, the number of variables is
reduced based upon expectations from results of prior
analyses and/or current hypotheses. A more objective
approach follows the advice of Bartels [73, 93], who
proposed establishment of the intrinsic data structure
within large data sets by use of PCA, and utilization of the
resulting smaller set of computed factors to represent the
subjects in subsequent analyses. Modern texts continue to
recommend PCA for variable reduction [94, 95]. Spectral
and spectral coherence data were first normalized (cen-
tered and shifted to have unit variance) so that eventual
factors reflect deviations from the average. The PCA-
generated smaller set of factors that represents a large
portion of the original variance results in a substantial
reduction of the ultimate variable number per subject.
This obviates the need for the ‘expert guided’ selection
of variable subsets for subsequent statistical analyses
with resulting risk of type 1 and type 2 statistical error.
A data set of uncorrelated (orthogonal) factors is produced
in which a small number of orthogonal factors are identi-
fied following varimax rotation.
Each factor is formed as linear combination of all input
variables with the weight or loading of each coherence
variable upon a particular factor as determined by the
PCA computation [73]. Meaning of outcome factors is
discerned by inspection of the loadings of the input vari-
ables upon each individual factor [73, 96]. Factor loadings
were treated as if they were primary neurophysiologic data
and displayed topographically [97, 98]. A display of ap-
proximately the highest 15 % of coherence loading values
was utilized to facilitate an understanding of individual
factors’ meaning (Figs. 2 and 3). This approach has been
used successfully for both spectral [99] and spectral coher-
ence [35, 100–102] data reduction and analysis.
FMAER: spectral signal and noise analysis
As described above, a normal subject’s 4 Hz FMAER
appears, upon scalp recording, in the form of a one second
4 Hz sine wave. Abnormal FMAERs – as observed in some
children with Landau-Kleffner syndrome or autism –
appear as noisy, distorted, or partial 4 Hz sine wave, or
occasionally just as low amplitude noise [68, 69]. ‘Noisy’ re-
sponses may reflect four possibilities: (1) there is no 4 Hz
response and the noise reflects residua of incomplete signal
averaging; (2) a low amplitude 4 Hz response is present but
is partially masked by noise from incomplete averaging; (3)
the response itself is distorted, causing a non-sinusoidal ap-
pearance (side-band noise); or (4) a combination of these
possibilities. A study of children with regressive autism
using spectral analysis of FMAERs formed from both
standard averaging and ‘plus-minus’ averaging [37] dem-
onstrated that, at baseline, children with absent language
demonstrated FMAERs manifesting distorted processing,
i.e. the 4 Hz auditory input to the ears produced, instead
of a clean 4 Hz scalp sinusoid, a broad-band 2–7 Hz re-
sponse [69]. Accordingly, spectral analysis was performed
on the current study subjects’ FMAERs in order to search
for evidence of auditory processing distortion in schizo-
phrenia prodrome. FFTs were formed on all subjects in
the current populations at 4 Hz (response frequency) as
well at 3 Hz and 5 Hz (sideband noise frequencies).
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Data analysis
Discrimination of subject groups by use of EEG spectral
coherence and spectral variables
Two-group DFA [96, 103, 104] was used in the current
study. As previously described [35], it produces a new ca-
nonical discriminant variable which maximally separates
the groups based on a weighted combination of the entered
variables. DFA defines the significance of a group separ-
ation, summarizes the classification of each subject, and
provides approaches to the prospective subjective classifica-
tion by means of the jackknifing technique [105–107].
The BMDP statistical package [108] was employed for
Fig. 2 Factor loadings for five coherence factors chosen to best differentiate clinically high risk (CHR) from neurotypical controls. Schematic heads
are shown in vertex view, scalp left to image left with nose above. Each one of the five black-bordered rectangles or squares displays, within its
borders, information relevant to a single one of the five coherence factors selected by discriminant function analysis (DFA; see text). For example,
the first row displays data describing the first factor chosen by DFA, Factor 26. Factor name is shown above and to the left of each image (e.g.
Factor 28), in yellow. Above the nose ‘COH’ indicates that the image displayed is a coherence factor. Where a factor requires more than one image to
illustrate relevant coherence loadings, they are separately labeled (e.g. Factor 26–1, Factor 26–2). The order of selection by DFA for each coherence
factor within the overall choice of eight factors is shown as a large white number. To the top right of each image is the relevant spectral frequency
and primary index electrode, displayed in yellow (e.g. 6 Hz P7). The colored regions within the images reflect the region and sign of coherence loadings
from the initial PCA. The index electrode for each image is show as a red circle bordered in white. Lines connect this index electrode to additional
electrodes (black dots). Line color reflects reduced (blue) or increased (red) coherence for the CHR population
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DFA (program 7 M) which yields the Wilks’ Lambda
statistic with Rao’s approximation. For the estimation of
prospective classification success, the jackknifing technique
was used [105–107] as provided within program 7 M. In
jackknifing for two-group DFA, the discriminant function
is formed on all subjects but one. The left-out subject is
subsequently classified. This initial left-out subject is then
folded back into the group (hence “jackknifing”), another
subject is left out, the DFA is performed again, and the
newly left-out subject classified. This process is repeated
until each individual subject has been left out and classified
on the basis of the ‘non-left-out’ subjects. The assessment
of prospective classification success is based upon a tally of
the left out subjects’ correct classification. This technique is
also referred to as the ‘leaving-one-out’ process and is gen-
erally taken as an estimate of future classification success
for populations of the size used in this project. A better es-
timation of classification success involves multiple split-half
replications as previously demonstrated on a large popula-
tion of autistic children [35]. It is notable that, within the
autism study the group, the average split half classification




Over the past 4 years, 35 CON subjects were recruited
and 57 putative patients with CHR were identified. Twenty
of the 57 manifested psychosis and an additional 15, al-
though non-psychotic, had been placed on medications by
the time of neurophysiologic evaluation. Accordingly, these
35 were excluded from the study target sample of unmedi-
cated patients with CHR. The remaining 22 non-psychotic,
unmedicated CHR patients made up the population to be
contrasted with the CON group. The final data analyses
were, therefore, based upon 35 control subjects and 22 sub-
jects with unmedicated CHR. Relevant, selected CON and
CHR group demographics are shown in Table 1.
EEG data were collected on the full population of 92
subjects and all were utilized for the purpose of coherence
and spectral variable reduction by PCA so as to maximize
the information/variance content within the PCA analyzed
data set.
There were no significant differences between the CON
and CHR groups in terms of handedness and sex. Signifi-
cant difference in mean age between these two groups was
managed by removing the effect of age upon variables,
Fig. 3 Factor loadings for three spectral factors chosen to best differentiate clinically high risk (CHR) from neurotypical controls. Schematic heads
are shown as for Fig. 2. Each of the three black-bordered squares displays information relevant to one of the three spectral factors selected by
discriminant function analysis (DFA; see text). Above the nose “FFT” signifies the image displayed is a spectral factor. Relevant spectral bands and
electrodes are shown above and to the right. The order of selection by DFA for each spectral factor within the overall choice of eight factors is
shown as a large white number. For example, the first square displays data for FFT Factor 19 involving 24-Hz activity at electrode C4 and was the
fourth factor chosen by DFA. The colored regions within the images reflect the region and sign of spectral loadings from the initial PCA. Color of
a small associated arrow reflects reduced (blue) or increased (red) spectral activity for the CHR population
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prior to use in discriminant analysis, using statistical
regression.
Factor development by PCA
Data reduction (factor formation) was independently
performed for the 4,416 spectral coherence variables and
the 1,536 spectral variables. For PCA on the coherence
data, results demonstrated, after varimax rotation, a good
condensation of variance upon a small number of factors.
After varimax rotation, the first coherence factor accounted
for 2.98 % of the total variance contained within the full set
of the original 4,416 coherence variables. Five factors
accounted for 15.14 % of the original variance, and the full
40 factors accounted for 77.82 % of the overall variance.
For PCA on the spectral data, results demonstrated even
stronger data condensation. After varimax rotation the first
spectral factor accounted for 14.13 % of the total original
variance, five factors accounted for 44.07 % of the variance,
and the full 40 factors accounted for 95.92 % of the total,
original variance. Age at study was regressed (BMDP-6R)
from all factors before use in subsequent analyses. Loadings
of original coherence and spectral variables upon corre-
sponding summary factors are illustrated in Figs. 2 and 3.
Discriminant function analysis (DFA)
Two-group stepwise discriminant function analysis (BMDP
7 M) was instituted contrasting groups CON (n = 35) and
CHR (n = 22), where coherence and spectral factors were
allowed to enter (F to enter 4.0, to remove 3.996). Results
are shown in Table 2. As evident, the F statistic ap-
proximation to Wilks’ Lambda was statistically signifi-
cant (P ≤0.00001). Five coherence and three spectral
factors were utilized (Table 3). The first three variables
chosen and five of the eight chosen variables were coher-
ence factors. Initial classification was 91.2 % correct over-
all (CON, 88.6 %; CHR, 95.5 % correct). The classification
success upon completion of jackknifing was 86.0 % correct
overall (CON, 85.7 %; CHR, 86.4 % correct). The groups
where displayed as a histogram on the canonical discrim-
inant variable (generated from the eight chosen factors)
showing a mostly bimodal distribution (Fig. 4).
Factor loadings
Figure 1 illustrates the standard placement for the 24
EEG electrode locations utilized, whereas Figs. 2 and 3
illustrate the loading patterns for the five chosen coherence
factors and for the three chosen spectral factors, respect-
ively, as utilized in the above DFA. Three of the five coher-
ence factors involved numerous coherence loadings and,
for the purpose of clarity, more than one image was utilized
Table 1 Control and high risk population demographics
Variable Controls Behavioral high risk Fisher exact test
n = 35 n = 22
Sex 14 males 11 males n/s
21 females 11 females
Handedness 34 right 20 right n/s
1 left 2 left
Mean ± SD
Age at study 19.175 ± 5.690 13.679 ± 3.240 T-test = 4.04;
P ≤0.0002
n, group population size; n/s, not statistically significant; P, probability
Table 2 Discriminant function analysis controls (CON) vs. clinical
high risk (CHR)
(1) Standard analysis
Group Percent Number of subjects classified
Correct CON CHR
CON 88.6 31 4
CHR 95.5 1 21
TOTAL 91.2
(2) Jackknife analysis
Group Percent Number of subjects classified
Correct CON CHR
CON 85.7 30 5
CHR 86.4 3 19
TOTAL 86.0
(3) Eight factors chosen to make discrimination, in order of choice
Overall estimated significance
1. COH 26 Wilk’s lambda = 0.419







COH, Coherence factor; FFT, Spectral factor; DF, Degrees of freedom for F test;
F, F statistic; P, Estimated probability
Table 3 Sample frequency modulated auditory evoked response
(FMAER) scores
Mean ± SD
Variable Controls High risk Probability
3 Hz-TP9 0.0331 ± 0.102 0.0301 ± 0.055 n/s
4 Hz-TP9 0.6892 ± 1.707 0.5471 ± 0.584 n/s
5 Hz-TP9 0.0456 ± 0.014 0.1441 ± 0.039 n/s
3 Hz-TP10 0.0022 ± 0.055 0.0407 ± 0.058 n/s
4 Hz-TP10 0.8177 ± 0.531 0.9479 ± 0.708 n/s
5 Hz-TP10 0.0539 ± 0.008 0.1231 ± 0.027 n/s
4 Hz, Targeted signal frequency; 3 Hz, 5 Hz, Side band frequencies; TP9, TP10,
Respective left and right posterior temporal regions, expected sites of maximum
left and right sided FMAER response (typical FMAER waveforms, normal and
abnormal, may be viewed in on-line references [64, 65]); n/s, Not significant by
Student’s t-test
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for demonstration, e.g. the first coherence Factor 13 is
depicted in three separate images. Each image is shown in
vertex view, i.e. from above; the left ear is shown to the left
and the nose above.
In each coherence factor image the index electrode and
primary EEG frequency are named top right and the refer-
enced electrode is also shown in red with a white circle.
Blue or red lines with arrow tips indicate the other involved
electrode (black circle) for each involved coherence pair.
Blue lines indicate reduced coherence for the CHR group
and red lines indicate increased coherence for the CHR
group in the featured DFA. Three coherence factors
demonstrated reduced coherence (Fac 26, 23, 13) and
two increased coherence (Fac 18, 28). Note that the first
two chosen factors manifest reduced coherence. Thus,
although both reduced and increased coherence are
observed, reduced coherence predominates. Also note,
in Fig. 2, that long distance coherence (coherence other
than to adjacent electrode) predominates. No single coher-
ence factor demonstrated a combination of decreased and
increased factor loadings. Four coherence factors involved
both hemispheres (Fac 26, 18, 13, 28) and one factor just
involved the right hemisphere (Fac 23). Involved spectral
bands were limited to the theta (Fac 26, 23, 13, 28) and
slow beta (Fac 18) spectral bands.
The colored background in the illustrated coherence
factors indicates the coherence loading from the original
PCA which, in combination with the loading of the
PCA-produced factors on the discriminant canonical
variable, determines the color of the lines (red or blue,
see below). Regions involved by coherence factor index
electrodes (red, white circle) are temporal – six (within Fac
26, 18, 13), occipital – two (Fac 23, 13), and frontal – one
(Fac 28). Of the six temporal index electrodes, all involved
the posterior temporal regions, three left and three right
sided. All six coherence factors involved primarily long
distance associations. None involved predominantly short
distance associations.
For each of the three spectral (FFT) factors used in the
DFA, regions involved are illustrated in color, which re-
flects loading of the regions’ spectral content upon the
given factor in the PCA. Next to each region is a small
arrow, the color and direction of which reflects spectral
change for the CHR group in the DFA (red, up, increase
for CHR group; blue, down, reduction in CHR group).
Just one factor demonstrated increased CHR spectral
magnitude (Fac 19) and two manifested decreased mag-
nitude (Fac 25, 34). All spectral factors reflected one sin-
gle spectral band: delta (Fac 25), theta (Fac 34), and beta
(Fac 19). Areas involved by the spectral factors included
the central-parietal (Fac 4, 25, 34), temporal (Fac 25),
and occipital (Fac 34) regions. None of these regions are
typically associated with eye or muscle artifact.
FMAER data analysis
The FMAER paradigm was performed on the 35 CON
and 22 CHR subjects. A standard average was created as
well as a plus-minus average. The former creates an aver-
age combination of the signal response, average of noise
within the response, and residual background noise left
after averaging. The latter produces an estimate of the re-
sidual background noise left after averaging [37, p. 61].
Both the standard and the plus-minus average response
were spectral analyzed by BESA from 3 through 5 Hz
across all 24 channels utilizing the common average refer-
ence. Subtraction of spectral analysis of the plus-minus
Fig. 4 Clinical high risk (CHR) and neurotypical control (CON) population distributions on the discriminant function analysis-derived canonical
discriminant variable. Population distributions are shown for the CON (green) and CHR (red) groups. The X axis is the canonical discriminant, ranging
from +4.5 to −3.5 units, which was created by the DFA process utilizing the eight factors described in Table 2, part (3). The Y axis represents
subject number
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average from that of the standard average created a spec-
tral difference plot where random background noise is re-
moved but the response remains. Ideally, the 3 Hz and
5 Hz sideband spectral values should be zero and the 4 Hz
component should be prominent. When the subtracted
values for the groups were compared by Student’s t-test,
no significant differences were observed for any frequency
or electrode. Table 1 shows the results for the bilateral
posterior-inferior temporal electrodes TP9 and TP10
(Fig. 1), electrodes that typically reflect maximal FMAER
scalp amplitude [64, 65]. Thus, there was no FMAER evi-
dence for any difference in response (at 4 Hz) magnitude
or response distortion (at 3 or 5 Hz) between the CHR
and the CON group at the two electrodes typically show-
ing greatest response amplitude [68, 69]. Note the large
difference in mean magnitude between the 4 Hz signal
and the adjacent 3 and 5 Hz sideband noise components
for both studied groups. In other words, both groups man-
ifested normally appearing FMAER responses.
Table 4 illustrates the expected large SOPS scores
differences between the CON and CHR groups.
Discussion
The objectives of the present study included the develop-
ment of neurophysiological descriptors of schizophrenia
prodrome (CHR) derived from ambient resting EEG. The
descriptors were expected to fulfill a series of criteria, in-
cluded (1) freedom from artifact contamination; (2) being
objective and bias free; (3) useful in the quantitative classi-
fication/identification of schizophrenia prodrome (CHR);
(4) useful in creation of putative, quantitative biomarker
for CHR; (5) clinically interpretable; and (6) facilitating
assessment of the functional integrity of the STG.
First, although infrequently emphasized, artifact may
significantly interfere with group study results that involve
quantification of EEG. Excessive artifact adds noise, thereby
obscuring discovery of significant group differences (type 2
statistical error, false negatives), or presents asymmetrically
within one group causing a spurious group difference
(type 1 error, false positives). In order to obviate or at
least minimize such possibilities, a four-part process was
undertaken. Initially, prominent artifact containing EEG
segments were removed by expert visual inspection of
EEG. Then, eye blink was computationally eliminated by a
source analysis technique [87–89]. Next, small residua of
eye movement and muscle were removed by a regression
technique [91]. Finally, higher frequencies above 30 Hz
(gamma band) were excluded from analysis, in agreement
with literature suggesting that such gamma activity is
strongly dominated by cranial muscle activity [61]. As a
result of the above process, factor loading patterns do not
suggest artifactual origins. Moreover, the statistical regres-
sion assures that utilized variables are ‘artifact free’, i.e. sta-
tistically uncorrelated with (orthogonal to) quantitative
estimates of artifact sources.
Second, as originally proposed by Bartels [73, 93], and
subsequently refined for use with neurophysiological
data [74] and utilized in this laboratory [35, 74, 100, 102],
PCA constitutes an objective way to demonstrate the
fundamental structure within a data set and simultaneously
an objective way to reduce variable number without need
for a priori intervention. In this study of coherence data, 40
factors represented 78 % of the information (variance)
within the 4,416 original spectral coherence variables per
subject. For spectral data, 40 factors represented 96 %
of the information within the 1,536 variables per subject.
This constitutes a substantial, unbiased reduction of data
dimensionality for both spectral and coherence data sets.
The high retention of variance indicates that, while redu-
cing data dimensionality, the PCA process preserved the
majority of information contained within the original data
set variables.
Third, stepwise discriminant analysis (DFA) between
the CON and prodrome (CHR) groups demonstrated suc-
cessful group separation with 91 % correct initial subject
classification. This was done on the basis of eight vari-
ables, yielding a favorable subject to variable ratio of 57/8,
approximately 7:1 [109]. More importantly, jackknifing
[105, 106] demonstrated 86 % correct classification for
both groups, a favorable indicator [103, 110] for the
prospective ‘diagnostic utility’ of EEG derived spectral
and coherence data.
Fourth, the DFA canonical discriminant function vari-
able graph (Fig. 4) showed a bimodal distribution between
the CON and CHR. This raises the possibility that such a
composite univariate discriminant variable formed on lar-
ger populations might serve to facilitate identification of
response to intervention and/or subsequent conversion to
schizophrenia. For example, it is speculated that a given
CHR intervention appearing to have little or no positive
clinical effect might, in fact, move a subject or subjects
Table 4 Structured Interview for Prodromal Syndromes (SIPS) –
Scale of Prodromal Symptoms (SOPS) scores
Mean ± SD
Variable Controls High risk T-test Probability
PMAX 0.486 ± 0.781 4.333 ± 0.658 19.720 0.0000
PAVG 0.177 ± 0.177 2.429 ± 0.985 10.020 0.0000
NMAX 0.114 ± 0.323 1.875 ± 0.409 7.680 0.0000
NAVG 0.033 ± 0.017 1.395 ± 0.304 5.880 0.0000
DMAX 0.200 ± 0.531 2.810 ± 0.273 9.090 0.0000
DAVG 0.071 ± 0.215 1.202 ± 0.835 6.090 0.0000
GMAX 0.171 ± 0.514 3.381 ± 1.600 8.940 0.0000
GAVG 0.057 ± 0.172 2.131 ± 1.264 7.480 0.0000
P, positive symptoms; N, negative symptoms; D, disorganized symptoms;
G, general symptoms; MAX, maximum of six scale scores per symptom type,
per subject; AVG, average of six scale scores per symptom type, per subject
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along the EEG discriminant from the CHR towards the
CON region. Perhaps combinations of such apparently
clinically silent, but favorably EEG active, interventions
might in aggregate prove to be of combined clinical value.
To facilitate the above, PCA and DFA analyses performed
for this study allow new subjects (or subjects before and
after intervention) to be passed through factor formation
and discriminant classification.
Fifth, factor loading plots (Figs. 2 and 3) showed coher-
ence patterns determined by the intrinsic data structure
and did not manifest the typical, orderly left-right inter-
hemispheric and anterior-posterior intra-hemispheric
coherence patterns often pre-selected for analysis. Index
coherence electrodes were mostly located over temporal
lobes, predominantly involving the posterior temporal re-
gions. Next, most prominent were occipital and frontal
index electrodes. Although factors representing both de-
creased and increased coherence were observed, reduced
coherence predominated, with long distance coherence
patterns prevailing. From the seven DFA-selected spectral
factor plots, none involved the prefrontal and only one
the temporal region suggesting successful avoidance, or
at least minimization, of spurious artifact dominated
variables [40–42].
In agreement with many studies suggesting temporal
lobe abnormalities in schizophrenia [33, 71, 72, 111–119]
and schizophrenia prodrome [33, 112, 113], the current co-
herence findings strongly implicate the bilateral temporal
areas. Reduced posterior temporal connectivity might be
relevant in terms of the complex language disorders in
schizophrenia [120] that presumably extend as well to CHR
[121]. Our coherence findings are also in line with the stud-
ies of Oertel-Knöchel et al. [71, 72], who found functional
MRI (fMRI) evidence of reduced connectivity with the pla-
num temporale and the STG within schizophrenics and
close relatives. These authors speculated that such findings
might be associated with psychotic symptoms, especially
auditory hallucinations. Moreover, Mou et al. [122] showed
that schizophrenics who report auditory verbal hallucina-
tions and who also demonstrated measured deficits in voice
identity recognition, manifest impaired frontal-temporal
connectivity. The current study’s coherence factors 18,
13, and possibly 28 may be consistent with such altered
frontal-temporal connectivity. In addition, the current
findings of mixed but predominantly widespread reduced
coherence in the awake resting state contradict prior
speculations that increased coherence presents a primary
schizophrenia biomarker [46].
In contrast to the current study’s coherence findings
implicating reduced connectivity with both posterior
temporal regions, the FMAER data demonstrate normal
primary receptive auditory processing in the cortex of
both STG. This finding stands in contrast with earlier
reports, as summarized in Methods, that in some patients
with the Landau-Kleffner syndrome [68] and regressive
autism [69], the FMAER may be absent and/or distorted.
A likely interpretation of the current results is that, in
CHR, there is normal initial/early cortical processing of
the auditory inputs within the STG but that the STG re-
gions manifest impaired connectivity with other cortical
areas that are broadly important in higher level language
processing. Putative auditory processing dysfunction
in CHR may depend more upon altered access of other
regions to the posterior temporal regions and less on
language processing within the STG itself – where, in
contrast, the defects appear to exist in Landau-Kleffner
syndrome and regressive autism.
Our findings of widespread alteration of cortical connect-
ivity in schizophrenia prodrome augment recent findings in
animal models of schizophrenia that emphasize abnormal-
ities of functional interactions among various thalamic,
frontal, and temporal regions [123–125]. Although progress
has been made in avoidance of eye and muscle contamin-
ation within quantitative EEG studies, there remain funda-
mental issues with cleanly accessing and quantifying ‘true’
brain generated delta and gamma band signals that appear
most relevant in animal studies which record directly from
brain. The process of scalp EEG artifact avoidance no doubt
diminishes or degrades true brain delta and gamma signals.
Accordingly, current findings cannot exclude potentially
relevant delta and gamma coherence differences in CHR.
However, current data provide robust indications of a
statistically significant CHR cortical difference in CHR at
frequencies outside the delta and gamma bands. More work
needs to be performed to obviate continuing technical
hurdles in processing scalp-recorded EEG.
It must also be emphasized that EEG-based evidence
of altered cortical connectivity in CHR should not be
considered causal per se. The origins of CHR are likely to
involve environmental, developmental, anatomical, gen-
etic, and/or neurochemical factors yet to be conclusively
elucidated. Such factors may bring about the behavioral
syndrome known as CHR and its associated, potentially
identifying, EEG coherence changes.
Conclusion
This study constitutes a demonstration that, following
careful artifact management and objective variable num-
ber reduction while maximizing information retention,
waking EEG significantly separates patients with CHR
(prodromal) schizophrenia from neurotypical controls.
The importance of these results rests partly on the relative
simplicity and low cost nature of ambient awake EEG data
recordings in comparison to the higher cost and complex-
ity of MRI and fMRI data collection processes.
It is also to be noted that EEG data, including passive,
specialized auditory stimulation (FMAER), provide add-
itional information – when processed as show above – that
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augment fMRI-based findings. Current data reinforce prior
fMRI findings of temporal lobe dysfunction in schizophre-
nia. Current EEG data further suggest that auditory halluci-
nations and auditory processing abnormalities may indeed
reflect abnormal connectivity with the posterior temporal
lobes but not with associated auditory processing dysfunc-
tion within the bilateral superior temporal gyri themselves.
In addition to successfully classifying individual subjects,
the canonical discriminant function might also serve as a
quantitative biomarker. It is speculated that potentially
useful therapeutic interventions might be identified by
their effectiveness in moving individual subjects from their
initial position along the canonical (biomarker) axis (Fig. 4)
as determined by a pre-treatment study, towards the
neurotypical end of the axis on the basis of a second
post-treatment study following therapeutic intervention.
Furthermore, it is speculated that the initial position along
the biomarker axis might serve to identify those subjects
with prodrome syndrome who are destined to convert to
full psychosis/schizophrenia.
However, further studies on larger populations will be
required to confirm the demonstrated classification suc-
cess as well as to establish these hypothetical possibilities
regarding use of the discriminant function as a scaled
biomarker.
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